Form 4: Theriva Biologics CEO/CFO Granted 475,000 Stock Options

Steven A. Shallcross, CEO and CFO of Theriva Biologics, Inc., was granted 475,000 stock options with an exercise price of $0.241.

Summary

• Steven A. Shallcross, CEO and CFO of Theriva Biologics, Inc. (TOVX), was granted 475,000 stock options.
• The options have an exercise price of $0.241 per share.
• The grant date for these options was January 5, 2026.
• These options will vest pro rata on a monthly basis over a 36-month period, commencing February 1, 2026.
• The expiration date for these stock options is January 4, 2033.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is a standard practice for incentivizing performance and retention, generally viewed as a neutral to slightly positive event for corporate governance and alignment of interests. It doesn't indicate immediate financial performance but rather a long-term compensation strategy.

Positives

• Aligns management's interests with long-term shareholder value through equity incentives.
• Provides a retention mechanism for a key executive (CEO and CFO).

Negatives

• Potential for future dilution if options are exercised, increasing the number of outstanding shares.

Risks

• The value of the options is dependent on the future market price of Theriva Biologics, Inc. common stock exceeding the exercise price of $0.241.
• Options will only vest if the executive remains employed by the company for the 36-month vesting period.

Future Outlook

The vesting schedule of the stock options over 36 months indicates an expectation of continued executive tenure and performance tied to long-term company growth.

Industry Context

Granting stock options to key executives is a common practice in the biotechnology and pharmaceutical industry, particularly for companies like Theriva Biologics, Inc., to incentivize leadership, align their interests with shareholders, and retain talent in a competitive market. This practice is a standard component of executive compensation packages.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also potential for increased shareholder value if executive incentives lead to improved company performance.
• Employees: May signal stability in executive leadership and a commitment to long-term growth.

Next Steps

• The stock options will begin vesting on a monthly basis starting February 1, 2026, over the next 36 months.
• Steven A. Shallcross may choose to exercise these options at any point after they vest and before their expiration date of January 4, 2033, assuming the stock price is favorable.

Key Dates

Recommendation

A Form 4 filing detailing an executive stock option grant is a routine disclosure and typically does not warrant a change in investment recommendation on its own. While it aligns executive incentives with shareholder value, it doesn't provide new information on the company's operational or financial performance that would drive a 'buy' or 'sell' decision. Investors should 'hold' and continue to monitor broader company fundamentals and market conditions.

Keywords

Theriva Biologics, TOVX, Steven A. Shallcross, Stock Options, CEO, CFO, Equity Compensation, Form 4, Insider Transaction, Executive Compensation, Rule 10b5-1